The Effect of Fluid Overload on Clinical Outcome in Southern Chinese Patients Undergoing Continuous Ambulatory Peritoneal Dialysis.
Qunying Guo, Jianxiong Lin, Jianying Li...
https://pubmed.ncbi.nlm.nih.gov/26152580/Actively Recruiting
Led by First Affiliated Hospital, Sun Yat-Sen University · Updated on 2026-06-29
194
Participants Needed
1
Research Sites
35 weeks
Total Duration
This clinical trial studies patients undergoing incremental peritoneal dialysis PD, focusing on whether using icodextrin solution can delay the need to shift from low dose to full dose dialysis within the first year. The study aims to evaluate the effect of icodextrin on fluid removal and clinical outcomes like peritonitis, anuria, hospitalizations, mortality, and quality of life. Patients are randomly assigned to two groups to compare icodextrin with standard glucose-based solutions in managing fluid overload during incremental PD. Participants are randomized 11 to receive either icodextrin Extraneal or hypertonic dextrose solution for their long night dwell when overhydration is detected by bioimpedance analysis ECWTBW 9 or edema. Both groups start with three bags of 2L glucose solution daily, adjusting when overhydration occurs. Patients are monitored every two months for fluid status, clinical symptoms, medication, and dialysis prescriptions. Treatment changes and supportive medications are provided as needed, and patients may switch to full dose dialysis based on clinical signs. Throughout the study, participants undergo regular assessments including fluid status measurement, blood and urine tests, peritoneal function tests, and quality of life surveys. Clinical events such as infections, hospitalizations, dialysis modality changes, and mortality are recorded up to 12 months. The primary outcome is the time to shift from low dose to full dose dialysis. Secondary outcomes include time to first peritonitis, anuria, hospitalization, technical failure, mortality, cardiovascular survival, and quality of life scores. The total duration of participation is about one year with ongoing monitoring.
CONDITIONS
Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis
X
Xiao Yang, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor
Baxter Healthcare Corporation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive incremental peritoneal dialysis with either icodextrin or hypertonic dextrose solution for long night dwell when overhydration occurs. They start with a low dose glucose regimen and adjust treatment based on fluid status monitored every 2 months.
Visits every 2 months for fluid status and clinical assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Qunying Guo, Jianxiong Lin, Jianying Li...
https://pubmed.ncbi.nlm.nih.gov/26152580/Carlo Garofalo, Silvio Borrelli, Toni De Stefano...
https://pubmed.ncbi.nlm.nih.gov/30604150/Bernadette Thomas, Sarah Wulf, Boris Bikbov...
https://pubmed.ncbi.nlm.nih.gov/26209712/Käthe Goossen, Monika Becker, Mark R Marshall...
https://pubmed.ncbi.nlm.nih.gov/32033860/Claudio Ronco, Christian Verger, Carlo Crepaldi...
https://pubmed.ncbi.nlm.nih.gov/25762355/Edwina A Brown, Peter G Blake, Neil Boudville...
https://pubmed.ncbi.nlm.nih.gov/32063219/S J Davies, L Phillips, A M Griffiths...
https://pubmed.ncbi.nlm.nih.gov/9853287/Ghada A Ankawi, Nancy I Woodcock, Arsh K Jain...
https://pubmed.ncbi.nlm.nih.gov/28781885/Hao Yan, Wei Fang, Aiwu Lin...
https://pubmed.ncbi.nlm.nih.gov/27751610/Steven Guest, John K Leypoldt, Michelle Cassin...
https://pubmed.ncbi.nlm.nih.gov/28096442/First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor
Baxter Healthcare Corporation
Collaborating Sponsor